Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. - Wikidata - awgldk - TriplyDB

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

http://www.wikidata.org/entity/Q33689451

about

Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis.Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains.Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.

P2860

Q33586699-FCD541A0-B99B-46DC-A34F-95BE0597937C Q33977947-2255EB5F-846B-4911-81BE-45AB1EB035A9 Q33980069-D1B94F27-CC8D-417D-B08D-BC1A55DDFE49 Q34107094-B7299132-AE16-4547-8214-E4613452CC7C Q39469535-D804F08C-28BC-44BF-A221-223B00FA1423 Q39558119-3487A6B4-EF5F-4074-BE2B-68E47EE827E0 Q39559768-1052F1A9-15CC-4A7D-A5F4-92A03A703F94

P2860

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

http://www.wikidata.org/entity/Q33689451

description

1998 nî lūn-bûn

@nan

1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

@ast

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

@en

type

label

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

@ast

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

@en

prefLabel

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

@ast

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

@en

P1433

Q33689451-BC98491C-985F-454E-80FD-6D592C7A7C6C

P1476

Q33689451-4BD8DA1A-0CB4-4D7F-B825-FFD91250BEEF

P2093

Q33689451-091C4550-09DF-41AF-9402-641142886CF3

Q33689451-25648BFD-171C-4EA6-BBD7-F9DA8ADFF849

Q33689451-30A13D0C-9A03-444B-AEB2-481E86EFEBD3

Q33689451-3F346BB3-C503-4F95-BBEB-08E3BC75E102

Q33689451-7D5E2E12-4C79-4705-808C-75DAEEEB2468

Q33689451-9C7DFC57-F6D0-4D64-BD18-19216F359EBF

P2860

Q33689451-02586197-CC15-40BD-92EB-74597C02DFD5

Q33689451-06F6B92B-187E-4A7F-9923-17CDC2F7DDCF

Q33689451-3C61909A-D554-420A-A90A-20E1A16AAC0E

Q33689451-41364F13-506B-477B-AE93-BDC16315CB39

Q33689451-452A75C7-E7FB-46DD-96FC-051CC519F84C

Q33689451-568E7F88-A54B-499D-94A3-4A063C22EB2F

Q33689451-63DD7774-9576-462F-BC2B-CE380A763EF0

Q33689451-6E334C76-700C-4723-A3CA-47B8267440DE

Q33689451-75A57AAD-98D0-4D19-A2D8-D418630A44BF

Q33689451-79F3A20B-E605-4CC6-B9D4-7767E14E4C63

P304

Q33689451-894E63D7-2E61-46A4-9CC9-F4CC52D1F643

P31

Q33689451-A815F338-EC0F-4CA9-B6B1-5027CB0EA23C

P407

Q33689451-55947926-567B-4AF8-897C-FFFA5E94C223

P433

Q33689451-755DEB0B-FE29-4764-ACB0-FCA1D8BBC992

P478

Q33689451-D44F3513-E153-4FC7-8605-7B5D9736505C

P577

Q33689451-EEF98D47-4689-46C4-9DF1-0B27FFD078E7

P698

Q33689451-CCC939EF-F089-4ED5-8DC6-7BBB2E20E240

P932

Q33689451-97EECAE8-ADAF-438E-A78A-FEA90FEA9A0C

P1433

Antimicrobial Agents and Chemotherapy

P1476

Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis

@en

P2093

G W Kaatz

http://www.w3.org/2001/XMLSchema#string

H H Houlihan

http://www.w3.org/2001/XMLSchema#string

J R Aeschlimann

http://www.w3.org/2001/XMLSchema#string

M J Rybak

http://www.w3.org/2001/XMLSchema#string

R C Mercier

http://www.w3.org/2001/XMLSchema#string

S M Seo

http://www.w3.org/2001/XMLSchema#string

P2860

CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.

Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia

Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

In vitro activity of the new fluoroquinolone CP-99,219.

Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis

P304

254-256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

1998-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9527768

http://www.w3.org/2001/XMLSchema#string

P932

105396

http://www.w3.org/2001/XMLSchema#string